Insurance Barriers to High-Cost Anti-Infective Medications Post Allogeneic Hematopoietic Cell Transplant. (PubMed, Transplant Cell Ther) - Jul 12, 2025 - "Medical records of patients who received high-cost medications (mold-active triazoles and letermovir [LTV]) during their first allo-HCT (1/1/20 - 5/1/22) were evaluated for insurance type, ancestry/ethnicity, and stem cell source...In the azole (n=287, voriconazole n=162, posaconazole n=64, isavuconazole n=61) and LTV (n=191) groups, the median age was 61 (range 19-81) and 61 years (range 22-81), respectively, with 44% female overall...Neither insurance type nor transplant characteristics predicted the level of barrier, suggesting that all patients should be assessed for financial toxicity. Pharmacists played an integral role in overcoming the insurance barriers for these high-cost medications, and work is ongoing to expand our understanding of the financial issues impacting our patients."
Journal • Reimbursement • US reimbursement • Hematological Disorders • Hematological Malignancies • Oncology • Transplantation
|
|
Andrew Lin; Christina Cho; Grashma Vadakkel; Gunjan L Shah; Juliet Barker; Lauren DeRespiris; Mary Nauffal; Melinda Cook; Miguel-Angel Perales; Moneeza Walji; Samantha Brown; Sean Devlin; Sergio A Giralt; Stephanie Monaco-Cermak; Stephen Eng; Susan Murillo; Warren Fingrut
|